Zanidatamab
April 10, 2021
AACR
The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
Weisser et al.
Preclinical
April 10, 2021
AACR
ProTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics
Heinkel et al.
Preclinical
April 10, 2021
AACR
Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB
Von Rossum et al.
Zanidatamab
January 15, 2021
ASCO GI
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study
Meric-Bernstam et al.
Zanidatamab
January 15, 2021
ASCO GI
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study
Meric-Bernstam et al.
Zanidatamab
January 15, 2021
ASCO GI
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers (BTCs)
Pant et al.
Zanidatamab
November 22, 2019
ESMO Asia
Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumor
Oh et al.
Zanidatamab Zovodotin
April 14, 2018 - April 18, 2018
AACR
ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
Hamblett et al.
